The aim of this research was formulation and evaluation of mucoadhesive buccal tablet of ivabradine hydrochloride for the treatment of stable angina pectoris. Ivabradine hydrochloride is an anti-anginal drug used in the symptomatic management of stable angina pectoris. It has absolute bioavailability only 40% due to extensive hepatic first pass metabolism. Mucoadhesive buccal drug delivery system will avoid first pass metabolism due to which bioavailability of drug may be improved. The drug loss will be decreased in GI tract by minimizing dissolution of drug into the saliva by designing “core in cup” design. Identification and compatibility study of drug and excipients were carried out using melting point, FTIR and DSC studies. Ivabradine hydrochloride showed λmax at 286 nm in phosphate buffer pH 6.8 and linearity was 0.9997. Core tablet was prepared with the combination of HPMC K4M and polycarbophil. Ethyl cellulose was used as a backing layer, found to be providing the desired release. Results of pre compressional and post compressional were found to be within the limits. Varying the amount of HPMC K4M and amount of polycarbophil have significant effect on mucoadhesive strength (Y1), % drug release at 6 hour (Y2) and % swelling index (Y3). Optimized batch shows Mucoadhesive strength (0.317 N), % drug release at 6 hour (96.06 %) and % swelling index (33.52 %) is desired in case of buccal drug delivery. The ivabradine hydrochloride mucoadhesive tablet is a promising approach for the effective treatment of stable angina pectoris as it provides sustained drug release.
Loading....